Javed Shaikh, Director of RWE & HEOR, Axtria, explains how harnessing next-generation sequencing and AI-powered analytics ...

Sangamo Therapeutics, Inc.'s $18M Eli Lilly deal boosts CNS genomic medicines. Fabry gene therapy data in 2025 is key for ...

“Diagnosing Gaucher disease typically involves a combination of clinical evaluation, family history, and laboratory tests. A blood test to measure glucocerebrosidase enzyme activity is crucial in ...

CRISPR gene-editing technology offers curative potential for genetic diseases. The gene-editing market is projected to reach $30.8 billion by 2032. Top gene-editing pioneers include Intellia ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

The original Gene line-up have reunited and announced their first live show in over 20 years. Read NME‘s interview with frontman Martin Rossiter below, where he discusses what to expect from the ...

3. Potential New Partnerships: Sangamo is actively seeking collaborations for its Fabry disease program and CAR-Treg cell therapy programs, which could provide additional resources and expertise.

Fabry Disease (isa-vec): The company plans to ... fitelparvovec): Developed in partnership with Pfizer (NYSE:PFE), this gene therapy candidate reported positive top-line data from the Phase ...

And our Fabry gene therapy study continues to generate best-in-class data, with a pivotal data readout expected in mid-2025.